Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients
This nonrandomized clinical trial examines humoral and cell-mediated immunity and longer-term safety following vaccination for respiratory syncytial virus (RSV) among recipients of lung transplant and allogeneic hematopoietic cell transplant.
Authors
- Victor H. Ferreira (ORCID: https://orcid.org/0000-0002-1472-9711)
- Meghan M. Aversa (ORCID: https://orcid.org/0000-0002-7361-0024)
- Sapna S. Humar (ORCID: https://orcid.org/0000-0001-7769-1311)
- Igor Novitzky‐Basso (ORCID: https://orcid.org/0000-0003-3748-3117)
- Pascal M. Lavoie (ORCID: https://orcid.org/0000-0002-2205-0362)
- Rochelle Johnstone
- Poramed Winichakoon (ORCID: https://orcid.org/0000-0003-2225-3706)
- Victoria G. Hall (ORCID: https://orcid.org/0000-0001-9353-0059)
- Adrian A Alexander
- Jonas Mattsson (ORCID: https://orcid.org/0000-0002-2163-6644)
- Roni Bitterman (ORCID: https://orcid.org/0000-0001-7495-3398)
- Faranak Mavandadnejad
- Rujun Kang
- Ailya Salman
- Xiaoqing Dang
- Deepali Kumar
- Sarayna Bala
- Madeline R. Kern-Smith
Institutions
- Alberta Health Services (CA)
- University Health Network (CA)
- University of British Columbia (CA)
- University of Calgary (CA)
- University of Toronto (CA)
- Foothills Medical Centre (CA)
- Princess Margaret Cancer Centre (CA)
- BC Children's Hospital Research Institute (CA)
- Chiang Mai University (TH)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-11-06
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.41946
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00